
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : SIFI
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Product Name : Akantior
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : SIFI
Deal Size : Inapplicable
Deal Type : Inapplicable
